{"entity":{"id":"terrapower-isotopes","kind":"company","name":"TerraPower Isotopes","aka":[],"tldr":"Bill Gates-backed producer of actinium-225 from thorium-229, building a Philadelphia facility to raise supply 20-fold.","summary":"TerraPower Isotopes, based in Bellevue, Washington, is the Bill Gates-backed producer of actinium-225 from thorium-229, building a Philadelphia facility intended to raise supply twenty-fold. It obtains actinium-225 from the decay of thorium-229 recovered from a legacy uranium-233 stockpile and holds supply agreements with Bayer, Bristol Myers Squibb and others. OnCo links it to targeted alpha therapy, alpha-emitter nanogenerators and the therapeutic isotope supply chain, to the radiopharmaceutical roadmap from iodine to actinium, and to the idea of recovering legacy radium-226 sources worldwide as feedstock. Manufacturing cost and time for radioactive medicines is the bottleneck it exists to relieve. Whether supply can grow fast enough for the alpha therapies now in phase 3 is the open question.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.terrapower.com/isotopes"}],"tags":["isotope-supply"],"related":[],"cancers":[],"sections":["radiopharma"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Bellevue, WA","country":"US","companyType":"radiopharma","website":"https://www.terrapower.com/isotopes","investors":[],"funding":[]},"route":"/companies/terrapower-isotopes/","neighbours":{"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"technology":[{"id":"actinium-225-supply","kind":"technology","name":"Actinium-225 supply: thorium stocks, accelerators and radium targets","route":"/technologies/actinium-225-supply/"},{"id":"alpha-nanogenerators","kind":"technology","name":"Alpha-emitter nanogenerators and daughter trapping","route":"/technologies/alpha-nanogenerators/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"},{"id":"therapy-isotope-supply-chain","kind":"technology","name":"Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)","route":"/technologies/therapy-isotope-supply-chain/"}],"roadmap":[{"id":"radiopharma-roadmap","kind":"roadmap","name":"Radiopharmaceutical roadmap: iodine → lutetium → actinium","route":"/roadmaps/radiopharma-roadmap/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"}],"idea":[{"id":"idea-reg-legacy-radium-recovery-ac225","kind":"idea","name":"Recover legacy radium-226 sources worldwide as the feedstock for actinium-225","route":"/ideas/idea-reg-legacy-radium-recovery-ac225/"}]}}